Fulcrum Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	-	80	2.81	6.34	19.16
Revenue Growth (YoY)	-	2752.05%	-55.77%	-66.91%	117.19%
Cost of Revenue	3.45	4.65	71.8	76.78	69.7
Gross Profit	-3.45	75.35	-69	-70.44	-50.54
Selling, General & Admin	28.67	36.45	41.67	41.69	30.52
Research & Development	52.66	58.73	-	-	-
Operating Expenses	81.32	95.18	41.67	41.69	30.52
Operating Income	-84.77	-19.83	-110.66	-112.13	-81.05
Interest & Investment Income	9.89	12.17	13.33	2.69	0.21
EBT Excluding Unusual Items	-74.88	-7.66	-97.34	-109.44	-80.85
Merger & Restructuring Charges	-	-2.06	-	-0.43	-
Pretax Income	-74.88	-9.73	-97.34	-109.87	-80.85
Net Income	-74.88	-9.73	-97.34	-109.87	-80.85
Net Income to Common	-74.88	-9.73	-97.34	-109.87	-80.85
Shares Outstanding (Basic)	63	62	61	45	35
Shares Outstanding (Diluted)	63	62	61	45	35
Shares Change (YoY)	2.21%	1.10%	36.27%	27.23%	39.47%
EPS (Basic)	-1.18	-0.16	-1.59	-2.44	-2.29
EPS (Diluted)	-1.18	-0.16	-1.59	-2.44	-2.29
Free Cash Flow	-60.38	-2.5	-91.47	-99.01	-80.19
Free Cash Flow Per Share	-0.95	-0.04	-1.49	-2.20	-2.27
Gross Margin	-	94.18%	-	-	-263.73%
Operating Margin	-	-24.79%	-3945.24%	-1768.12%	-422.97%
Profit Margin	-	-12.16%	-3470.05%	-1732.43%	-421.89%
Free Cash Flow Margin	-	-3.12%	-3261.07%	-1561.23%	-418.47%
EBITDA	-83.38	-18.24	-108.49	-109.72	-78.54
EBITDA Margin	-	-22.80%	-	-	-
D&A For EBITDA	1.39	1.59	2.17	2.41	2.52
EBIT	-84.77	-19.83	-110.66	-112.13	-81.05
EBIT Margin	-	-24.79%	-	-	-

Updated Feb 24, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q